COVID-19, asthma, and biological therapies: What we need to know

Mário Morais-Almeida, Rita Aguiar, Bryan Martin, Ignacio J. Ansotegui, Motohiro Ebisawa, L. Karla Arruda, Marco Caminati, Giorgio Walter Canonica, Tara Carr, Geoffrey Chupp, Jonathan Corren, Ignacio Dávila, Hae Sim Park, Nicola A. Hanania, Lanny Rosenwasser, Mario Sánchez-Borges, J. Christian Virchow, Anahí Yáñez, Jonathan A. Bernstein, Luis CaraballoYoon Seok Chang, Manana Chikhladze, Alessandro Fiocchi, Sandra N. González-Diaz, Luciana Kase Tanno, Michael Levin, Jose António Ortega-Martell, Giovanni Passalacqua, David B. Peden, Philip W. Rouadi, James L. Sublett, Gary W.K. Wong, Eugene R. Bleecker

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations

Abstract

Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.

Original languageEnglish (US)
Article number100126
JournalWorld Allergy Organization Journal
Volume13
Issue number5
DOIs
StatePublished - May 2020
Externally publishedYes

Keywords

  • Asthma
  • Biologics
  • COVID-19
  • Pandemic
  • SARS-CoV-2
  • Severe
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'COVID-19, asthma, and biological therapies: What we need to know'. Together they form a unique fingerprint.

Cite this